Business Standard

Dr Reddy's Q4 PAT may rise 28% YoY; margins likely to fall, say analysts

The pharmaceutical giant may witness some impact due to its large exposure of the business to Russia, and CIS regions.

pharma
Web Exclusive Premium

Harshita Singh New Delhi
Hyderabad-based drugmaker Dr Reddy’s Laboratories is set to announce results for the fourth quarter of FY22 (Q4FY22) on Thursday, May 19. Analysts expect the company to post revenue growth of 8-16 per cent in Q4FY22 on the back of decent sales across all geographies and a ramp-up in volumes of its Vascepa generic in the US.

The company’s net profit is expected to rise 28 per cent year-on-year (YoY), as per an average of estimates by four brokerages.
 
However, on a quarterly basis, it may register a decline in net profits due to cost pressures that may have also likely

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: May 18 2022 | 3:11 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com